- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00831753
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants
Immunogenicity Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Comparison to Infanrix®Hexa, at 2-4-6 Months of Age in Healthy Peruvian Infants
The study aims to confirm that, in Peruvian infants, the investigational DTaP-IPV Hep B-PRP~T vaccine has immunological and safety profiles that are comparable to those of the control vaccine that is already marketed (Infanrix®Hexa)
Primary Objective:
To demonstrate that the hexavalent DTaP-IPV-Hep B-PRP~T combined vaccine induces an immune response that is at least as good as the response following Infanrix®Hexa in terms of seroprotection rates to HB, one month after a three-dose primary series (2, 4 and 6 months)
Secondary Objectives:
- To describe in each group the immunogenicity to vaccine components (for DTaP-IPV-Hep B-PRP~T and Infanrix®Hexa) one month after the third dose of the primary series.
- To assess the overall safety in each group one month after each dose of the primary series and through the entire study.
연구 개요
상태
상세 설명
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Lima, 페루
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria :
- Two month old infant (50 to 71 days old) on the day of inclusion, of either gender
- Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg
- Mother negative for Hepatitis B surface Antigen (HBsAg) in approximately the last 30 days of pregnancy (≥ 36 weeks of amenorrhea) or in the 30 days post partum
- Informed consent form signed by both parents. If one or both parent(s) are under 18 years of age, the subject's grandparent(s) should also sign. An independent witness should also sign if the parent(s)/grandparent(s) are illiterate
- Able to attend all scheduled visits and to comply with all trial procedures
- Received Bacillus Calmette Guerin (BCG) vaccine between birth and one month of life in agreement with the national immunization calendar.
Exclusion Criteria :
- Participation in another clinical trial in the 4 weeks preceding the first trial vaccination
- Planned participation in another clinical trial during the present trial period
- Known systemic hypersensitivity to any of the vaccine components or history of a life threatening reaction to the trial vaccine or a vaccine containing the same substances
- Congenital or acquired immunodeficiency, or immunosuppressive therapy such as long-term (for more than 2 weeks) systemic corticosteroid therapy within the last four weeks
- Chronic illness at a stage that could interfere with trial conduct or completion
- Blood or blood-derived products received since birth
- Any vaccination in the 4 weeks preceding the first trial vaccination
- Any planned vaccination during the trial (until Visit 06), except the study vaccines, rotavirus vaccine and pneumococcal conjugate vaccines
- Documented history of pertussis, tetanus, diphtheria, poliomyelitis, hepatitis B or Haemophilus influenzae type b infection(s) (confirmed either clinically, serologically, or microbiologically)
- Previous vaccination against pertussis, tetanus, diphtheria, poliomyelitis, hepatitis B or Haemophilus influenzae type b infection(s)
- Known personal or maternal history of Human Immunodeficiency Virus, hepatitis B or hepatitis C seropositivity
- Known thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination
- History of seizures
- Febrile (temperature ≥ 38.0°C) or acute illness on the day of inclusion.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Group 1
DTaP-IPV-Hep B-PRP~T vaccine group
|
0.5 mL, Intramuscular
|
활성 비교기: Group 2
Infanrix® Hexa vaccine group
|
0.5 mL, Intramuscular
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Number of Participants Achieving Seroprotection for Anti Hep-B After a Primary Series of Vaccination With Either DTaP-IPV-Hep B-PRP~T or Infanrix Hexa™
기간: Day 150 (1 month after dose 3)
|
Anti-hepatitis B (Hep B) antibodies were measured by chemiluminescence detection.
Seroprotection was defined as a titer ≥ 10 mIU/mL.
|
Day 150 (1 month after dose 3)
|
Number of Participants Achieving Seroprotection to Vaccine Antigens After a Primary Series Vaccination With Either DTaP-IPV-Hep B-PRP~T or Infanrix Hexa™ Vaccine.
기간: Day 150 (1 month after dose 3)
|
Antibody titers were measured by chemiluminescence detection for hepatitis B (Hep B), by Farr type radioimmunoassay for Haemophilus influenzae type b (PRP), and by toxin neutralization test for diphtheria. Seroprotection criteria were defined as: Criteria 1: Anti-Hep B titer ≥ 10 mIU/mL; Anti-PRP titer ≥ 0.15 µg/mL; Anti-diphtheria titer ≥ 0.01 IU/mL. Criteria 2: Anti-Hep B titer ≥ 100 mIU/mL; Anti-PRP titer ≥ 1 µg/mL; Anti-diphtheria titer or ≥ 0.1 IU/mL. |
Day 150 (1 month after dose 3)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Geometric Mean Titers (GMTs) of Antibodies to Vaccine Antigens After a Primary Series of Vaccination With Either DTaP-IPV-Hep B-PRP~T or Infanrix Hexa™ Vaccine.
기간: Day 150 (1 month after dose 3)
|
Antibody titers were measured by chemiluminescence detection for hepatitis B (Hep B), by Farr type radioimmunoassay for Haemophilus influenzae type b (PRP), and by toxin neutralization test for diphtheria.
|
Day 150 (1 month after dose 3)
|
Number of Participants Reporting Solicited Injection Site or Solicited Systemic Reactions After Vaccination With Either DTaP-IPV-Hep B-PRP~T or Infanrix Hexa™ Vaccine.
기간: Day 0 up to Day 7 after each injection
|
Solicited Injection Site Reactions: Pain, Erythema, Swelling. Solicited Systemic Reactions: Pyrexia (Temperature), Vomiting, Crying, Somnolence, Anorexia, Irritability. Grade 3 reactions were defined as: Pain, cries when injected limb is moved or movement of injected limb is reduced; Erythema and Swelling ≥ 5 cm; Pyrexia > 39.5ºC; Vomiting ≥ 6 episodes per 24 hour or requiring parenteral hydration; Crying, > 3 hours; Somnolence, sleeping most of the time or difficult to wake up; Anorexia refuses ≥ 3 feeds/meals or refuses most feeds/meals; Irritability inconsolable. |
Day 0 up to Day 7 after each injection
|
공동 작업자 및 조사자
간행물 및 유용한 링크
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- A3L17
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
B형 간염에 대한 임상 시험
-
Pfizer완전한수막구균 B 질병호주, 폴란드, 핀란드, 체코
-
Canadian Immunization Research NetworkUniversity of British Columbia; University of Calgary; Dalhousie University; Université de...완전한
-
Jiangsu HengRui Medicine Co., Ltd.모집하지 않고 적극적으로
-
Hebei Senlang Biotechnology Inc., Ltd.Tongji Hospital모병
-
Masonic Cancer Center, University of Minnesota완전한난치성 B-혈통 백혈병 | 재발된 B 계통 백혈병 | 난치성 B 계통 림프종 | 재발된 B 계통 림프종미국
-
Shanghai Tongji Hospital, Tongji University School...모병
-
Fundamenta Therapeutics, Ltd.Anhui Provincial Hospital모병
DTaP IPV HB PRP~T vaccine에 대한 임상 시험
-
Sanofi Pasteur, a Sanofi Company완전한B형 간염 | 백일해 | 디프테리아 | 소아마비칠면조
-
Sanofi Pasteur, a Sanofi Company완전한B형 간염 | 백일해 | 파상풍 | 디프테리아 | B형 헤모필루스 인플루엔자페루, 멕시코
-
Sanofi Pasteur, a Sanofi Company완전한B형 간염 | 백일해 | 디프테리아 | 소아마비칠면조
-
Sanofi Pasteur, a Sanofi Company완전한
-
Sanofi Pasteur, a Sanofi Company완전한B형 간염 | 백일해 | 디프테리아 | 소아마비 | B형 헤모필루스 인플루엔자남아프리카
-
Sanofi Pasteur, a Sanofi Company완전한백일해 | 파상풍 | 디프테리아 | 소아마비 | B형 헤모필루스 인플루엔자아르헨티나
-
Sanofi Pasteur, a Sanofi Company완전한B형 간염 | 백일해 | 파상풍 | 디프테리아 | 소아마비콜롬비아, 코스타리카
-
Sanofi Pasteur, a Sanofi Company완전한
-
Sanofi Pasteur, a Sanofi Company완전한B형 간염 | 백일해 | 파상풍 | 디프테리아 | 소아마비 | 헤모필루스 인플루엔자 B형 감염멕시코
-
Sanofi Pasteur, a Sanofi Company완전한B형 간염 | 백일해 | 디프테리아 | 소아마비 | B형 헤모필루스 인플루엔자태국